XTL Biopharma 6-K Filing Shows Co. Received Letter From Nasdaq Listing Qualifications Dept. Indicating Co. Failed To Comply With $35M Market Value, $2.5M Shareholder Equity Requirements Oct. 17
Paul Quintaro